Depression: Five Million Americans May Benefit From Psychedelic Therapy - Newsweek
New research suggests psilocybin-assisted therapy could benefit millions of Americans with depression, with 56-62% of current treatment recipients potentially eligible if FDA approves. The study, involving Emory University, UW-Madison, and UC Berkeley, highlights the importance of understanding practical implementation challenges.
Reference News
New research suggests psilocybin-assisted therapy could benefit millions of Americans with depression, with 56-62% of current treatment recipients potentially eligible if FDA approves. The study, involving Emory University, UW-Madison, and UC Berkeley, highlights the importance of understanding practical implementation challenges.
Over 5 million Americans could benefit from psilocybin therapy for depression if approved by the FDA, according to a study published in the journal Psychedelics.
A study estimates 5.1 to 5.6 million Americans receiving depression treatment could qualify for psilocybin therapy if approved by the FDA, based on criteria from recent clinical trials.